Chlorthalidone
Mostrando 1-9 de 9 artigos, teses e dissertações.
-
1. Diuretics are Similar to Losartan on Echocardiographic Target-Organ Damage in Stage I Hypertension. PREVER-Treatment Study
Resumo A terapia de redução da pressão arterial (PA) melhora os parâmetros do ventrículo esquerdo (VE) na lesão a órgãos-alvo causada pela condição hipertensiva na hipertensão de estágio II; no entanto, se existem ou não diferenças relacionadas à classe de medicamentos nos parâmetros ecocardiográficos de pacientes com hipertensão estágio I
Arq. Bras. Cardiol.. Publicado em: 2019-01
-
2. Síntese e caracterização estrutural de complexos envolvendo os fármacos Maleato de Enalapril, Hidroclorotiazida e Clortalidona
A busca pelo entendimento do mecanismo de ação de medicamentos tem sido realizada constantemente no intuito de elucidar a estrutura molecular bem como os grupos funcionais de interesse, importantes para que haja uma atividade farmacológica adequada. Tendo em vista que o mecanismo de ação do fármaco anti-hipertensivo maleato de enalapril esteja vinculad
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 22/07/2011
-
3. Prevention of hypertension in patients with pre-hypertension : protocol for the PREVER-prevention trial
Background: Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular di
Publicado em: 2011
-
4. A comparison between diuretics and angiotensinreceptor blocker agents in patients with stage I hypertension (PREVER-treatment trial) : study protocol for a randomized double-blind controlled trial
Background: Cardiovascular disease is the leading cause of death in Brazil, and hypertension is its major risk factor. The benefit of its drug treatment to prevent major cardiovascular events was consistently demonstrated. Angiotensin-receptor blockers (ARB) have been the preferential drugs in the management of hypertension worldwide, despite the absence of
Publicado em: 2011
-
5. Determination of losartan associated with chlorthalidone or hydrochlorothiazide in capsules by capillary zone electrophoresis
Uma metodologia alternativa por eletroforese capilar de zona (ECZ) é proposta para a análise de losartan potássio (LOS) associado com clortalidona (CTD) ou hidroclorotiazida (HCT) em cápsulas, usando 50 mmol L-1 de tampão carbonato de sódio com detecção em 226 nm. O sistema de eletrólito foi otimizado, levando em consideração o perfil do pico, res
Journal of the Brazilian Chemical Society. Publicado em: 2007
-
6. Effects of chlorthalidone and diltiazem on myocardial ischemia in elderly patients with hypertension and coronary artery disease
OBJETIVE: Antihypertensive therapy with thiazides decreases coronary events in elderly patients. However, the influence of diuretics on myocardial ischemia has not been fully investigated. The aim of this study was to compare the effect of chlorthalidone and diltiazem on myocardial ischemia. METHODS: Following a randomized, double-blind, crossover protocol,
Arquivos Brasileiros de Cardiologia. Publicado em: 2001-04
-
7. Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone
BioMed Central.
-
8. Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?
The lowering of high blood pressure is supposed to protect target organs from hypertensive damage. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial was designed to compare the cardioprotective properties of three antihypertensives from different classes (lisinopril, amlodipine and doxazosin) with chlorthalidone. Despite effecti
BioMed Central.
-
9. A new era in hypertension research: discussing the findings of ALLHAT
The key question in hypertension research today is, "Does it matter how elevated blood pressure is lowered?" The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) initiated in 1994 serves as a model for comparative trials. Its strengths include its independent sponsorship, scope and design. The alpha-blocker arm was stopped
BioMed Central.